FIELD: immunology.
SUBSTANCE: disclosed are peptides derived from FOXM1 and capable of inducing a cytotoxic T-cell (CTL) in the presence of an antigen-presenting cell (APC) expressing HLA-A*01:01. Invention also describes: a coding polynucleotide; composition; methods for inducing APC and CTL; APC presenting HLA-A*01:01 and peptide; a method for inducing an immune response; method of treating and/or preventing a malignant tumor and/or preventing its postoperative recurrence; emulsion; set; as well as use of said inventions when preparing a pharmaceutical composition and a peptide screening method with ability to induce CTL.
EFFECT: this group of inventions can find application in therapy of diseases associated with FOXM1.
21 cl, 8 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE, OBTAINED FROM MPHOSPH1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2731099C2 |
| PEPTIDE OBTAINED FROM DEPDC1 AND VACCINE CONTAINING IT | 2016 |
|
RU2765574C2 |
| NEOANTIGENS AND THEIR APPLICATION | 2019 |
|
RU2805196C2 |
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
| T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
| NEOANTIGENS AND THEIR USE | 2019 |
|
RU2813924C2 |
| NEW ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION | 2018 |
|
RU2805674C2 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
| IMMUNO-INDUCING AGENT | 2016 |
|
RU2744843C2 |
